Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 10% in severe COVID-19
NCT04400058Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jun 2020
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of intravenous immunoglobulin G in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Octapharma. Primary endpoint: Proportion of Subjects Reaching Stabilization or Improvement in Clinical Status at Day 7. Started Jun 2020; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04400058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400058.